Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01379183 · ClinicalTrials.gov registry record · Phase 2
Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT01379183: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT01379183 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01379183, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
Magnetic Resonance Imaging (MRI) has proven to be a valuable imaging technique for suspected small bowel disease. This technique depends, in part, on adequate distension of the small bowel. This is accomplished by administering large volumes of a non-absorbable oral contrast material prior to the examination, which typically produces excellent distension of the distal small bowel and stomach, but poor distension of the proximal small bowel. Erythromycin is a common antibiotic that is known to promote stomach emptying and is used to treat diabetics with gastroparesis (poor stomach emptying.) The hypothesis of this study was that erythromycin will increase gastric emptying and hence improve small and large intestinal distention during MRI.
Interventions
- DRUG Placebo
- PROCEDURE Magnetic Resonance Imaging
- DRUG Erythromycin
- OTHER Barium Sulfate Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01379183
The ClinicalTrials.gov registry entry for NCT01379183 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01379183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01379183 about?
NCT01379183 is a clinical study titled "Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility". Magnetic Resonance Imaging (MRI) has proven to be a valuable imaging technique for suspected small bowel disease. This technique depends, in part, on adequate distension of the small bowel. This is accomplished by administering large volumes of a non-absorbable oral contrast material prior to the ex...
What is the current status of trial NCT01379183?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2011-06. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01379183?
The interventions under investigation include: Placebo (DRUG), Magnetic Resonance Imaging (PROCEDURE), Erythromycin (DRUG), Barium Sulfate Solution (OTHER).
Who is sponsoring clinical trial NCT01379183?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.